Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, New York Member, IMF Board of Scientific Advisors
12.22.07
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.
button next to the volume control in the
lower right hand corner.
print
related articles